ENZ: Enzo Biochem, Inc. Stock

by  •  • Comments Off on ENZ: Enzo Biochem, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 17.82
Enterprise Value ($M) -22.26
Book Value ($M) 46.62
Book Value / Share 0.89
Price / Book 0.38
NCAV ($M) 31.32
NCAV / Share 0.60
Price / NCAV 0.57

Profitability (mra)
Return on Invested Capital (ROIC) -0.43
Return on Assets (ROA) -0.22
Return on Equity (ROE) -0.30

Liquidity (mrq)
Quick Ratio 2.69
Current Ratio 3.04

Balance Sheet (mrq) ($M)
Current Assets 52.22
Assets 67.51
Liabilities 20.89
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 31.91
Operating Income -12.37
Net Income -26.08
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -26.26
Cash from Investing -0.55
Cash from Financing -4.19

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-17 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 ☐ TRANSITION REPORT P
2024-12-16 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 ☐ TRANSITION REPORT P
2024-10-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-06-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-02 18,076 428,065 4.22
2025-04-01 63,312 702,671 9.01
2025-03-31 44,177 858,624 5.15
2025-03-28 1,057 18,567 5.69

(click for more detail)

Similar Companies
BMY – Bristol-Myers Squibb Company EBS – Emergent BioSolutions Inc.
ELAN – Elanco Animal Health Incorporated HYAC – Haymaker Acquisition Corp. 4
JNJ – Johnson & Johnson


Financial data and stock pages provided by
Fintel.io